At present, there are three approved ADCs for the treatment of HER2-positive breast cancer, and these are trastuzumab-emtansine (T-DM1), trastuzumab-deruxtecan (TDXd), and sacituzumab-govitecan (Table 1). Here, ERBB2 is linked to breast cancer.